Research Library

By Morgan N. Fredell, Hagop M. Kantarjian, Ya-Chen Shih, Vivian Ho and Binata Mukherjee Current U.S. health care spending includes many areas of wasted expenditures. In this study, published in Cancer, the authors explore plans to optimize U.S. health care to provide greater benefits to patients: https://bit.ly/2TmeoDg

U.S. studies suggest that the Uber ride-sharing service may reduce alcohol-related driving fatalities. This study, published in the Journal of Epidemiology & Community Health, examines the effect of Uber on traffic deaths in South Africa, where driving fatalities are twice the global average and over 60 percent are alcohol-related.

The authors conducted mobile phone surveys on energy supply, demand and quality in 12 sub-Saharan African countries, finding that current grid and off-grid electricity supply is inadequate to meet consumers' demands.

The authors examine ways in which disruptive technologies could potentially help improve power sector development in African countries. 

The winner’s curse — overestimating the value of an asset and therefore overpaying — is often associated with acquisitions of publicly-traded firms but not with private acquisitions. Using an event study methodology for over 22,000 private acquisitions of U.S. firms between 1985 and 2015, the authors examine a possible winner’s curse for such acquisitions, testing variables to determine what characteristics make a private company more likely to overestimate the asset's value.

States with large African-American populations are more likely to have harsher incarceration practices, worse conditions of confinement and tougher policies toward juveniles compared with other states, according to a study led by Katharine Neill, the Alfred C. Glassell III Postdoctoral Fellow in Drug Policy.

Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. What determines the escalating prices of cancer drugs?

For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.

In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials.

Allowing the producer-dominated market to set drug prices has spiraled the cost of cancer drugs out of control. Drug pricing can be reduced while preserving the profit-making incentive, by linking price to a true measure of quality: preservation and meaningful prolongation of life.